HRP20170973T1 - Anti-c4.4a protutijela i njihova uporaba - Google Patents

Anti-c4.4a protutijela i njihova uporaba

Info

Publication number
HRP20170973T1
HRP20170973T1 HRP20170973TT HRP20170973T HRP20170973T1 HR P20170973 T1 HRP20170973 T1 HR P20170973T1 HR P20170973T T HRP20170973T T HR P20170973TT HR P20170973 T HRP20170973 T HR P20170973T HR P20170973 T1 HRP20170973 T1 HR P20170973T1
Authority
HR
Croatia
Prior art keywords
antibodies
Prior art date
Application number
HRP20170973TT
Other languages
English (en)
Croatian (hr)
Inventor
Lars Linden
Yong-Jiang Cao
Gabriele Leder
Beatrix Stelte-Ludwig
Axel Harrenga
Ricarda Finnern
Frank Dittmer
Anke Mayer-Bartschmid
Juergen Franz
Simone Greven
Jörg WILLUDA
Jan Tebbe
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of HRP20170973T1 publication Critical patent/HRP20170973T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20170973TT 2009-12-09 2010-12-08 Anti-c4.4a protutijela i njihova uporaba HRP20170973T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09178474 2009-12-09
EP10170797 2010-07-26
EP10798996.4A EP2510012B1 (en) 2009-12-09 2010-12-08 Anti-c4.4a antibodies and uses thereof
PCT/EP2010/069216 WO2011070088A1 (en) 2009-12-09 2010-12-08 Anti-c4.4a antibodies and uses thereof

Publications (1)

Publication Number Publication Date
HRP20170973T1 true HRP20170973T1 (hr) 2017-09-22

Family

ID=43629588

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20170973TT HRP20170973T1 (hr) 2009-12-09 2010-12-08 Anti-c4.4a protutijela i njihova uporaba

Country Status (27)

Country Link
US (2) US20120321619A1 (cg-RX-API-DMAC7.html)
EP (2) EP2510012B1 (cg-RX-API-DMAC7.html)
JP (3) JP5989544B2 (cg-RX-API-DMAC7.html)
KR (1) KR101931820B1 (cg-RX-API-DMAC7.html)
CN (1) CN102812047B (cg-RX-API-DMAC7.html)
AR (1) AR079340A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010329904B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012013915A8 (cg-RX-API-DMAC7.html)
CA (1) CA2783338A1 (cg-RX-API-DMAC7.html)
CY (1) CY1119051T1 (cg-RX-API-DMAC7.html)
DK (1) DK2510012T3 (cg-RX-API-DMAC7.html)
ES (1) ES2632748T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20170973T1 (cg-RX-API-DMAC7.html)
HU (1) HUE034847T2 (cg-RX-API-DMAC7.html)
IL (1) IL219801A (cg-RX-API-DMAC7.html)
IN (1) IN2012DN05175A (cg-RX-API-DMAC7.html)
LT (1) LT2510012T (cg-RX-API-DMAC7.html)
MX (1) MX2012006593A (cg-RX-API-DMAC7.html)
NZ (1) NZ600470A (cg-RX-API-DMAC7.html)
PL (1) PL2510012T3 (cg-RX-API-DMAC7.html)
PT (1) PT2510012T (cg-RX-API-DMAC7.html)
RS (1) RS56161B1 (cg-RX-API-DMAC7.html)
RU (1) RU2577977C2 (cg-RX-API-DMAC7.html)
SI (1) SI2510012T1 (cg-RX-API-DMAC7.html)
TW (1) TWI488642B (cg-RX-API-DMAC7.html)
WO (1) WO2011070088A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201203498B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5881604B2 (ja) * 2010-06-15 2016-03-09 国立大学法人大阪大学 癌予後判定可能な抗体、および癌予後判定方法
JP2014515753A (ja) * 2011-04-21 2014-07-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 新規な結合剤−薬物複合体（ａｄｃ）およびそれらの使用
JP2014117191A (ja) * 2012-12-13 2014-06-30 Fisheries Research Agency リン酸化中性スフィンゴミエリナーゼ１、抗リン酸化中性スフィンゴミエリナーゼ１抗体、中性スフィンゴミエリナーゼ１変異体、及びそれらの用途
JP2017534251A (ja) * 2014-09-09 2017-11-24 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ａｇｒ２およびその受容体ｃ４．４ａに対する遮断モノクローナル抗体
JP6720208B2 (ja) * 2015-04-17 2020-07-08 スプリング バイオサイエンス コーポレーション Ｃ４．４ａを検出するための抗体、組成物、及び免疫組織化学法
BR112018011270A2 (pt) * 2015-12-04 2018-11-21 Univ California anticorpo isolado, composição farmacêutica, e, métodos para tratamento ou redução da taxa de recorrência de um câncer em um paciente e para detecção de células tronco do câncer.
WO2017156280A1 (en) * 2016-03-09 2017-09-14 Viba Therapeutics, Inc. Methods of treating cancer using monoclonal antibodies to agr2 and c4.4a
JP7617603B2 (ja) 2017-01-11 2025-01-20 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｒ－スポンジン（ｒｓｐｏ）サロゲート分子
CA3050133A1 (en) 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
JP7052389B2 (ja) * 2018-02-07 2022-04-12 株式会社三洋物産 遊技機
WO2020014271A1 (en) 2018-07-09 2020-01-16 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses
JP2021530238A (ja) * 2018-07-20 2021-11-11 デューク ユニバーシティ がんの処置のための抗ｌｙｐｄ３ ｃａｒ ｔ細胞療法
US20210324434A1 (en) * 2018-11-08 2021-10-21 National University Corporation Kagawa University Method for producing rare sugar-containing composition and rare sugar-containing composition
CN111349164B (zh) * 2018-12-21 2023-05-26 艾比玛特医药科技（上海）有限公司 糖基磷脂酰肌醇锚定糖蛋白（c4.4a）的单克隆抗体及其应用
AU2020298326A1 (en) * 2019-06-21 2022-01-27 Children's National Medical Center Methods and composition for a binding molecule targeting cancer cells expressing SSX2 peptide 41-49 in HLA-A*0201 context
EP4054602A4 (en) 2019-11-08 2023-12-06 Mayo Foundation for Medical Education and Research EPHA3 TARGETED CAR-T CELLS FOR TREATING TUMORS
JP2023549854A (ja) 2020-11-16 2023-11-29 スロゼン オペレーティング， インコーポレイテッド 肝臓特異的Ｗｎｔシグナル増強分子およびその使用
KR20250021299A (ko) 2022-03-16 2025-02-12 펜틱사팜 아게 Lypd3에 대한 항체
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. CHELETARIANS AND BIFUNCTIONAL CONJUGATES

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
JP4318752B2 (ja) * 1996-05-31 2009-08-26 ヘルス・リサーチ・インコーポレーテッド 抗エンドグリンモノクローナル抗体および抗血管新生治療におけるその使用
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1220919A2 (en) * 1999-09-29 2002-07-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Metastasis-associated antigen c4.4a
AU2002314495A1 (en) * 2001-06-20 2003-01-02 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
RU2404810C9 (ru) * 2004-06-01 2015-06-20 Дженентек, Инк. Конъюгаты антитело-лекарственное средство и способы
US8105602B2 (en) * 2006-12-08 2012-01-31 Tactic Pharma, Llc Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof
JP2014515753A (ja) * 2011-04-21 2014-07-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 新規な結合剤−薬物複合体（ａｄｃ）およびそれらの使用

Also Published As

Publication number Publication date
RU2577977C2 (ru) 2016-03-20
WO2011070088A1 (en) 2011-06-16
ES2632748T3 (es) 2017-09-15
BR112012013915A8 (pt) 2017-12-26
JP2018019721A (ja) 2018-02-08
EP3144323A3 (en) 2017-05-31
TWI488642B (zh) 2015-06-21
AU2010329904A1 (en) 2012-06-14
LT2510012T (lt) 2017-07-25
JP5989544B2 (ja) 2016-09-07
TW201134485A (en) 2011-10-16
RS56161B1 (sr) 2017-11-30
CY1119051T1 (el) 2018-01-10
CN102812047A (zh) 2012-12-05
PL2510012T3 (pl) 2017-09-29
JP6240696B2 (ja) 2017-11-29
US20120321619A1 (en) 2012-12-20
IN2012DN05175A (cg-RX-API-DMAC7.html) 2015-10-23
ZA201203498B (en) 2015-10-28
IL219801A (en) 2016-08-31
SI2510012T1 (sl) 2017-08-31
MX2012006593A (es) 2012-06-28
JP2016104820A (ja) 2016-06-09
KR101931820B1 (ko) 2018-12-21
EP3144323A2 (en) 2017-03-22
IL219801A0 (en) 2012-07-31
JP2013513369A (ja) 2013-04-22
PT2510012T (pt) 2017-07-13
EP2510012B1 (en) 2017-04-19
US20170158775A1 (en) 2017-06-08
CN102812047B (zh) 2015-08-26
NZ600470A (en) 2015-02-27
CA2783338A1 (en) 2011-06-16
AU2010329904B2 (en) 2015-07-09
BR112012013915A2 (pt) 2017-01-10
KR20120116958A (ko) 2012-10-23
AR079340A1 (es) 2012-01-18
DK2510012T3 (en) 2017-07-31
EP2510012A1 (en) 2012-10-17
HUE034847T2 (en) 2018-03-28
HK1178920A1 (en) 2013-09-19
RU2012128343A (ru) 2014-01-20

Similar Documents

Publication Publication Date Title
IL219801A0 (en) ANTI-C4.4a ANTIBODIES AND USES THEREOF
EP2494062A4 (en) ANTI-GLP-1R ANTIBODIES AND THEIR USES
ZA201107486B (en) Anti-tnf-x antibodies and their uses
IL244197A0 (en) Antibodies against cd100 and methods of using them
EP2478110A4 (en) CLASS I ANTI-CEA ANTIBODIES AND USES THEREOF
IL209309A0 (en) Anti-fn14 antibodies and uses thereof
ZA201105573B (en) Novel anti-alpha5beta1 antibodies and uses thereof
PL2354161T3 (pl) Przeciwciało anty -NR10 i jego zastosowanie
IL216731A (en) And antibodies against p95 – her2 and their uses
IL200012A0 (en) Anti-robo4 antibodies and uses therefor
IL226383B (en) Antibodies against ccl20, preparations containing them and their uses
IL216014A0 (en) Antibodies immunorective with heregulin-her3 complexes, compositions comprising the same and uses thereof
ZA201201218B (en) 3-polylysine conjugates and the use thereof
IL205355A0 (en) Anti- hepcidin antibodies and uses thereof
ZA201108310B (en) Blocking anti-dkk-1 antibodies and their uses
IL220536A0 (en) Anti - bv8 antibodies and uses thereof
PL2493930T3 (pl) Udoskonalone przeciwciała przeciwko ludzkiej fraktalkinie i ich zastosowania
SI2354161T1 (sl) Anti-NR10 protitelo in njegova uporaba
IL214527A0 (en) Anti-mst1r antibodies and uses thereof
GB0903151D0 (en) Antibody uses and methods
AP2011005854A0 (en) Novel GP41 antigens.
GB0812277D0 (en) Antibody and uses thereof
GB0906115D0 (en) Antibody and uses thereof
ZA200905136B (en) Anti-robo4 antibodies and uses therefor